Biomarkers

BioIVT will be hosting a virtual Emerging Technologies in Diagnostics Symposium on  Thursday, October 29 (10am-1pm ET). “The diagnostic assay landscape is changing rapidly as the demand for faster, less expensive, more precise diagnostics continues to grow,” said Cathie Miller, Director of Product Marketing, Personalised Medicine at BioIVT. “We wanted to take this opportunity to […]

Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the EIT Health Wild Card competition […]

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 […]

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used by laboratories around the world […]

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Currently, there is a huge […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its mission, the PMC publishes The Case for Personalized Medicine. Since the first […]

Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable […]

Phenotypic Drug Discovery With High Content Screening Sponsored by PerkinElmer Early drug discovery used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system – cells, tissue, or organisms – and asking the question, did this entity affect the phenotype? Target Based or Phenotypic Screening? With the rise of […]

Advanced Therapeutic Antibody Discovery with Multiplexed Screening Sponsored by Sartorius Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease. It is predicted that by the year 2020 there will be 70 therapeutic antibodies on the market, generating revenue of $125 […]